FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2896785102> ?p ?o ?g. }

• W2896785102 abstract "ANAVEX®2-73, a selective sigma-1 receptor agonist was studied in a Phase 2a trial with 32 mild-to-moderate Alzheimer's disease patients for 57 weeks. MMSE baseline range was 16-28. ANAVEX®2-73 demonstrated a favorable safety profile. An ANAVEX®2-73 concentration-response relation was observed using exploratory endpoints MMSE (Mini-Mental State Examination) and ADCS-ADL (Alzheimer's Disease Co-operative Study – Activities of Daily Living). The full exome (DNA) and transcriptome (RNA) of attainable AD patients were sequenced using Illumina HiSeq 2500 with an average sequencing depth of 70x, resulting in the analysis of 33,311 genes and 860 pathways, using non-linear rule based Formal Concept Analysis as implemented in KEM. Systematic analysis identifies several genetic variants impacting the response including SIGMAR1(rs1800866), ANAVEX®2-73 putative target, and COMT(rs113895332/rs61143203), a gene involved in memory function. Excluding these variants from the study population, still leaving about 80% of the population, results in improved MMSE and ADCS-ADL scores (p<0.05, Cohen's d effect size >0.5 and Specificity=100%). In addition, we observe that high RNA expression levels for SIGMAR1 are associated with improved outcome as measured by MMSE and ADCS-ADL. Including patients with milder disease stage (baseline MMSE ≥20) and the exclusion of AD patients carrying SIGMAR1 mutation results in a score improvement of 1.7 MMSE and 3.9 ADCS-ADL, respectively at week 57. The additional exclusion of the COMT mutation results in a score improvement of 2.0 MMSE and 4.9 ADCS-ADL, respectively for the same period. Both effects would be clinically meaningful. This is the first full genomic analysis of ANAVEX®2-73 in AD patients resulting in the identification of actionable genetic variants. Consistent results were found using both DNA and RNA and multiple endpoints and time points. The data provides support to further precision medicine clinical development of ANAVEX®2-73 utilizing genetic biomarkers leading to a pre-specified population, who demonstrated a confirmed response with ANAVEX®2-73. Further larger clinical studies in several indications are planned or underway. Detailed results will be presented at the conference." @default.
• W2896785102 created "2018-10-26" @default.
• W2896785102 creator A5026873181 @default.
• W2896785102 creator A5027072747 @default.
• W2896785102 creator A5027720445 @default.
• W2896785102 creator A5029821240 @default.
• W2896785102 creator A5048619898 @default.
• W2896785102 creator A5068015254 @default.
• W2896785102 creator A5074090472 @default.
• W2896785102 creator A5076838888 @default.
• W2896785102 date "2018-07-01" @default.
• W2896785102 modified "2023-10-16" @default.
• W2896785102 title "P4‐206: FULL GENOMIC ANALYSIS OF ANAVEX ^® 2‐73 PHASE 2A ALZHEIMER'S DISEASE STUDY IDENTIFIES BIOMARKERS ENABLING TARGETED THERAPY AND A PRECISION MEDICINE APPROACH" @default.
• W2896785102 doi "https://doi.org/10.1016/j.jalz.2018.07.027" @default.
• W2896785102 hasPublicationYear "2018" @default.
• W2896785102 type Work @default.
• W2896785102 sameAs 2896785102 @default.
• W2896785102 citedByCount "0" @default.
• W2896785102 crossrefType "journal-article" @default.
• W2896785102 hasAuthorship W2896785102A5026873181 @default.
• W2896785102 hasAuthorship W2896785102A5027072747 @default.
• W2896785102 hasAuthorship W2896785102A5027720445 @default.
• W2896785102 hasAuthorship W2896785102A5029821240 @default.
• W2896785102 hasAuthorship W2896785102A5048619898 @default.
• W2896785102 hasAuthorship W2896785102A5068015254 @default.
• W2896785102 hasAuthorship W2896785102A5074090472 @default.
• W2896785102 hasAuthorship W2896785102A5076838888 @default.
• W2896785102 hasConcept C126322002 @default.
• W2896785102 hasConcept C143998085 @default.
• W2896785102 hasConcept C2779134260 @default.
• W2896785102 hasConcept C2781197716 @default.
• W2896785102 hasConcept C2908647359 @default.
• W2896785102 hasConcept C54355233 @default.
• W2896785102 hasConcept C71924100 @default.
• W2896785102 hasConcept C86803240 @default.
• W2896785102 hasConcept C99454951 @default.
• W2896785102 hasConceptScore W2896785102C126322002 @default.
• W2896785102 hasConceptScore W2896785102C143998085 @default.
• W2896785102 hasConceptScore W2896785102C2779134260 @default.
• W2896785102 hasConceptScore W2896785102C2781197716 @default.
• W2896785102 hasConceptScore W2896785102C2908647359 @default.
• W2896785102 hasConceptScore W2896785102C54355233 @default.
• W2896785102 hasConceptScore W2896785102C71924100 @default.
• W2896785102 hasConceptScore W2896785102C86803240 @default.
• W2896785102 hasConceptScore W2896785102C99454951 @default.
• W2896785102 hasIssue "7S_Part_29" @default.
• W2896785102 hasLocation W28967851021 @default.
• W2896785102 hasOpenAccess W2896785102 @default.
• W2896785102 hasPrimaryLocation W28967851021 @default.
• W2896785102 hasRelatedWork W1963672760 @default.
• W2896785102 hasRelatedWork W1987019626 @default.
• W2896785102 hasRelatedWork W2064219387 @default.
• W2896785102 hasRelatedWork W2119974004 @default.
• W2896785102 hasRelatedWork W2791579310 @default.
• W2896785102 hasRelatedWork W2901961843 @default.
• W2896785102 hasRelatedWork W2971623491 @default.
• W2896785102 hasRelatedWork W3030370935 @default.
• W2896785102 hasRelatedWork W3210338963 @default.
• W2896785102 hasRelatedWork W4285149509 @default.
• W2896785102 hasVolume "14" @default.
• W2896785102 isParatext "false" @default.
• W2896785102 isRetracted "false" @default.
• W2896785102 magId "2896785102" @default.
• W2896785102 workType "article" @default.